Also, the overexpression of p53 is linked to a poorer prognosis and more advanced clinicopathological characteristics in individuals with renal cell carcinoma, suggesting that p53 could be a potential target for RCC treatment [34]. This evidence concerns the gene TP53 and renal cell carcinoma.